BioWorld

Jan. 13, 2004

Threshold's Oncology Products Emerge Through $41M Series B

Stepping into the biotech spotlight, cancer drug developer Threshold Pharmaceuticals Inc. raised $41 million in a second round of financing that attracted new and existing investors. (BioWorld Today) Read More

Regeneron CEO: Beware 'Fibs' From Prospective Dealmakers

BioPort Gets Anthrax Vaccine Contract Worth Up To $245M

Concurrent Raises $15M, Partners With Intel On 'Machine Learning'

Inhibitex Series E Raises $20M To Advance Veronate, Aurexis

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...